Berberine inhibits SREBP-1-related clozapine and risperidone induced adipogenesis in 3T3-L1 cells

Phytotherapy Research

Volumn 24, Issue 12, 2010, Pages 1831-1838

  Hu, Yueshan ^a   Kutscher, Eric ^a,b,c   Davies, Gareth E ^a,b,c  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

^b Avera Health   (United States)

^c UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

3T3 L1; adipogenesis; berberine; clozapine; risperidone; SREBP 1

Indexed keywords

ADIPONECTIN; BERBERINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CLOZAPINE; LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RISPERIDONE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ADIPOGENESIS; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN 3T3; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE EXPRESSION; IMMUNOBLOTTING; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WEIGHT GAIN; WESTERN BLOTTING;

3T3-L1 CELLS; ADIPOGENESIS; ANIMALS; BERBERINE; CELL DIFFERENTIATION; CELL SURVIVAL; CLOZAPINE; MICE; RISPERIDONE; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMALIA;

EID: 78649680341     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3204     Document Type: Article

References (30)

1. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB., 1999. Annual deaths attributable to obesity in the United States. JAMA 282: 1530-1538.
2. Baptista T, Martínez J, Lacruz A, et al,. 2006. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 51: 192-196.
3. Cernáková M, Kostálová D., 2002. Antimicrobial activity of berberine-a constituent of Mahonia aquifolium. Folia Microbiol (Praha) 47: 375-378.
4. Choi BH, Ahn IS, Kim YH, et al,. 2006. Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte. Exp Mol Med 38: 599-605.
5. Farwell WR, Stump TE, Wang J, Tafesse E, L'Italien G, Tierney WM., 2004. Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med 19: 1200-1205.
6. Fleischhaker C, Heiser P, Hennighausen K, et al,. 2008. Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. J Neural Transm 115: 1599-1608.
7. Gothelf D, Falk B, Singer P, et al,. 2002. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159: 1055-1057.
8. Hemmrich K, Gummersbach C, Pallua N, Luckhaus C, Fehsel K., 2006. Clozapine enhances differentiation of adipocyte progenitor cells. Mol Psychiatry 11: 980-981.
9. Ho YT, Yang JS, Lu CC, et al,. 2009. Berberine inhibits human tongue squamous carcinoma cancer tumor growth in a murine xenograft model. Phytomedicine 16: 887-890.
10. Hu Y, Davies GE., 2009a. Berberine increases expression of GATA-2 and GATA-3 during inhibition of adipocyte differentiation. Phytomedicine 16: 864-873.
11. Hu Y, Davies GE., 2009b. Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia. [Epub ahead of print]
12. Hu Y, Fahmy H, Zjawiony JK, Davies GE., 2010. Inhibitory effect and transcriptional impact of berberine and evodiamine on human white preadipocyte differentiation. Fitoterapia 81: 259-268.
13. Huang C, Zhang Y, Gong Z, et al,. 2006. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARgamma pathway. Biochem Biophys Res Commun 348: 571-578.
14. Joffe G, Takala P, Tchoukhine E, et al,. 2008. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69: 706-711.
15. Kong W, Wei J, Abidi P, et al,. 2004. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10: 1344-1351.
16. Kroeze WK, Hufeisen SJ, Popadak BA, et al,. 2003. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519-526.
17. Lean ME, Pajonk FG., 2003. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 26: 1597-1605.
18. Lee YS, Kim WS, Kim KH, et al,. 2006. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55: 2256-2264.
19. Malhotra AK., 2004. Candidate gene studies of antipsychotic drug efficacy and drug-induced weight gain. Neurotox Res 6: 51-56.
20. Müller-Wieland D, Kotzka J., 2002. SREBP-1: gene regulatory key to syndrome X? Ann NY Acad Sci 967: 19-27.
21. Newcomer JW., 2005. Second-generation (atypical) antipsychotics and metabolic effects a comprehensive literature review. CNS Drugs 19 (Suppl. l): 1-93.
22. Piyanuch R, Sukhthankar M, Wandee G, Baek SJ., 2007. Berberine, a natural isoquinoline alkaloid, induces NAG-1 and ATF3 expression in human colorectal cancer cells. Cancer Lett 258: 230-240.
23. Rayalam S, Yang JY, Ambati S, Della-Fera MA, Baile CA., 2008. Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother Res 22: 1367-1371.
24. Rege S., 2008. Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Austr NZ J Psychiatry 42: 369-381.
25. Sharpe JK, Byrne NM, Stedman TJ, Hills AP., 2005. Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication. J Am Diet Assoc 105: 612-615.
26. Vestri HS, Maianu L, Moellering DR, Garvey WT., 2007. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 32: 765-772.
27. Yang LH, Chen TM, Yu ST, Chen YH., 2007. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacol Res 56: 202-208.
28. Yang Z, Yin JY, Gong ZC, et al,. 2009. Evidence for an effect of clozapine on the regulation of fat-cell derived factors. Clin Chim Acta 408: 98-104.
29. Yin J, Xing H, Ye J., 2008. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57: 712-717.
30. Zhou LB, Chen MD, Wang X, et al,. 2003. Effect of berberine on the differentiation of adipocyte. Zhonghua Yi Xue Za Zhi 83: 338-340.